A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)

Summary

This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.

Timeline

Start

2003-03-19

Primary completion

2004-03-15

Completion

2004-03-15

Publications

• Background Cryer B, Binkley N, Simonelli C, Lewiecki EM, Lanza F, Chen E, Petruschke RA, Mullen C, de Papp AE. A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am J Geriatr Pharmacother. 2005 Sep;3(3):127-36. doi: 10.1016/s1543-5946(05)80019-4.

Drugs

Indications